Image Credit: Canva
Can a toothache be the reason for someone's cancer? An England based doctor and health content creator @Choji_ES who posts on X, formerly Twitter on reproductive health related content revealed a case where a man went to the dentist due to pain in his jaw and when the tooth was pulled out, a cancer was found in his private part.
The same case also been mentioned by Baridueh Badon (MD, MSc, MBA), who allows posts healthcare content on the same microblogging platform, by the username @BadonB.
In this case, a man went to a dentist for a simple toothache, only to discover that he had cancer. This happened to a 78-year-old healthy man, who suffered pain in his lower jaw and noticed a loose tooth. When he went to the dentist, he decided to get his tooth remove to ease his pain. However, despite the removal, his jaw started to swell again. Confused, the man was recommended for a CT scan and something unexpected happened.
It was Metastatic Prostate Cancer.
As per an African proverb, it is true that the head and the body are one; what affects one may touch the other.
Prostate cancer starts in the prostate gland, which is a part of a man's reproductive system. When it spreads to other parts of the body, like the jaw, it is called metastatic prostate cancer. But, why exactly the jaw? This is because the jawbone is rich in blood and active bone marrow, which makes it a comfortable place for cancer cells to settle and grow.
As per a 2023 study in the Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, titled Mandibular metastasis from prostate cancer that clinically mimicked osteosarcoma: A case report, noted that in men, 11% of jawbone metastases originated from the prostate gland.
Warning Signs Dentists Look For:
These may seem minor, but they could hint at something serious. Early detection is life-saving.
Prostate cancer is the 4th common cancer globally and is most prone to men who are over 40. Every year, it claims about 400,000 lives worldwide.
Earlier in November, six-time Olympic cyclist Sir Chris Hoy was diagnosed with stage-4 prostate cancer, which was announced in February. This six-time Olympic champion revealed that he had a pain in his shoulder when he was 47, which did not go away. "I was still lifting weights in the gym, still physically active. You are used to having aches and pains, but this one did not go away."
The prostate is a small walnut-shaped gland in men that produces seminal fluid that nourishes and transports sperm. It occurs when abnormal cells form and grow in that gland.
Experts say that not all prostate cancer is deadly. There are cancers that are slow-growing and will not affect a man's lifespan, which is found in 1 in 3 men over 50. Then there is a small number of very aggressive prostate cancers which move quickly and cause harm, this is why regular screening is important.
Chris too has called for more, younger men to be tested, including those with a family history of the disease.
Credit: iStock
While research shows women need more sleep than men due to brain function, hormones, and multitasking, females around the globe are struggling to get enough sleep, according to experts.
A 2016 study by the Sleep Research Centre at the UK’s Loughborough University found that women needed 20 minutes more sleep because of multitasking and performing more complex brain tasks during the day.
But, the American Academy of Sleep Medicine (AASM), revealed that an estimated 30 percent of women fail to get sufficient sleep.
Hormones, mood disorders, and caregiving responsibilities, coupled with professional pressures and stress, are the major reasons driving up insomnia and other sleep issues among women.
“Women around the world face a higher burden of sleep difficulties because their sleep cycles are tightly interlinked with hormonal shifts that occur throughout life,” Dr. Janhvi Siroya Shah, Sleep Specialist from the University of Bern, Switzerland, told HealthandMe.
The gender gap in sleep is real, as revealed by the recent ResMed Global Sleep Survey 2026, which showed that 56 percent of women get a good night's sleep only four days or fewer per week, compared to 50 percent of men.
Women were also 48 percent more likely to report problems falling asleep than men (42 percent). More than 50 percent of women felt waking up not feeling rested for 1-2 nights per week or more, compared to 46 percent of men.
The study flagged stress or anxiety as the biggest barrier to consistent, quality sleep (39 per cent), followed by work-related responsibilities (37 per cent) and household duties (31 per cent) among women.
Speaking to HealthandMe, Dr. Kirti Kadian, from the Department of Pulmonary Critical Care & Sleep Medicine at AIIMS Bhopal, said: “Women experience disproportionate sleep challenges globally, largely because their bodies undergo repeated physiological transitions that influence how sleep is regulated.”
The experts cited the main reasons as
All these factors can alter mood regulation, increase nighttime alertness, and disrupt the architecture of sleep itself.
Dr Kadian said that hormonal fluctuations across the life course -- especially during the menopausal transition -- can affect circadian rhythm, airway stability, pain sensitivity, and the nervous system’s response to stress.
“When these biological changes coincide with external stressors, such as multitasking, emotional labor or caregiving demands, women become far more vulnerable to insomnia and unrefreshing sleep,” Shah said.
The prevalence of sleep disorders increases from about 16–42 percent in pre-menopause to around 39–47 percent in peri-menopause and up to 35–69 percent in post-menopause, indicating that sleep disturbances become more common as women progress through different reproductive stages.
“Declining levels of estrogen and progesterone can disrupt the body’s sleep regulation and trigger symptoms like hot flashes and night sweats, while reduced melatonin may make it harder to fall and stay asleep,” Dr. Kadian explained.
In addition, certain medical conditions that are more common in women, such as thyroid disorders, anemia, and autoimmune diseases, can also negatively affect sleep and overall health.
Poor sleep also significantly affects both physical and mental health, increasing the risk of
The Harvard Medical School suggested that to get a better sleep cycle women should:
Credit: iStock
While early-stage research raised hopes of oral semaglutide (GLP-1 pill) slowing down the progression of Alzheimer’s disease, results of a new large-scale clinical trial have rendered it ineffective.
Evoke and Evoke+ -- the randomized, double-blind, placebo-controlled phase 3 trials conducted across 566 sites in 40 countries -- showed that semaglutide led to no significant difference after two years.
The findings, published in the Lancet journal, however, revealed that the popular weight loss drug can lead to significant reductions in several biological markers of Alzheimer’s disease.
Yet, it did not help slow the progression of the neurodegenerative disease, said an international team of researchers, including those from the University of California-San Diego.
"Oral semaglutide was not efficacious in slowing clinical progression in participants with early Alzheimer's disease," they said in the paper.
"Safety and tolerability of semaglutide in early Alzheimer's disease is consistent with studies in other indications," the team added.
The studies are the first major phase 3 trials to investigate this possibility in people with early Alzheimer’s disease.
The researchers conducted the trial on about 3,800 patients aged 55-85 years. The patients received either up to 14 mg of oral semaglutide daily or a placebo pill.
After two years, no significant difference was seen in slowing down the cognitive disease's progression in patients taking semaglutide and patients taking the placebo.
"The results of the large evoke(+) trials do not support the efficacy of 14 mg/day of semaglutide given for up to 156 weeks in participants with biomarker-confirmed Alzheimer's disease in the MCI or mild dementia stage," the researchers said.
While “GLP-1 [drugs] have given us so many wonderful results," the trial results are "disappointing,” and “a setback for the field”, endocrinologist Daniel Drucker was quoted as saying to the Scientific American.
Drucker says there are many potential explanations why oral semaglutide didn’t work as hoped. The fatty-acid structure surrounding semaglutide might have prevented it from being able to penetrate certain brain regions, such as the hippocampus, which controls memory and cognitive function.
Alzheimer's disease is a progressive neurodegenerative disease characterised by gradual cognitive and functional decline.
It is one of the most common forms of dementia and mostly affects adults over the age of 65.
Over seven million people in the US, 65 and older, live with the condition, and over 100,00 die from it annually.
The disease is believed to be caused by the development of toxic amyloid and beta proteins in the brain, which can accumulate and damage cells responsible for memory.
Early symptoms of Alzheimer's disease include forgetting recent events or conversations. Other signs include:
Credit: iStock
In the year 1947, on the remote Scottish island of Jura, George Orwell sat hunched over a typewriter in a farmhouse, engaged in a desperate race against time to finish his masterpiece, 1984, while a ‘slow-motion plague’ consumed his lungs.
The man who was born in Motihari, Bihar, was suffering from tuberculosis. He would cough up blood and frequently collapse out of sheer exhaustion, even as he typed the final warnings of a dystopian future. He finished the book in December 1948 and died just over a year later.
Orwell’s story is a haunting reminder that TB has always been a disease of the displaced. As we approach World Tuberculosis Day this year with the theme ‘Yes! We Can End TB: Led by countries, powered by people, we face a sobering reality.
We have the modern tools that Orwell lacked, but the global narrative remains trapped in an outdated cycle where technological potential far outstrips operational reality. To end this disease, we must stop viewing TB through a narrow clinical lens and start addressing the systemic inefficiencies that leave out millions.
For decades, a diagnosis of drug-resistant TB (DR-TB) was a near-death sentence even with treatment. Patients faced a grueling 18 to 24-month treatment regimen involving thousands of pills and daily painful injections that often caused permanent side effects like deafness.
With the introduction of the BPaLM regimen (Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin), this tide seems to have turned. The all-oral four-drug treatment, touted as a medical miracle, has slashed recovery time for drug-resistant strains to just six months.
However, even a magic pill cannot overcome a broken system. We must distinguish between clinical success and social success. A patient might technically be cured of the bacteria, but if they lose their job or suffer from social stigma during those six months, the system has still failed them.
Statistically, men bear a higher burden of TB, yet they are often the hardest to bring into the care net. According to the World Health Organization (WHO), men account for approximately 55 per cent of all TB cases globally, compared to 33 per cent for women and 12 per cent for children.
This is not a biological accident; it is a structural failure. Gendered social norms often prevent men from seeking care until the disease is advanced. As primary earners, the prospect of losing wages – combined with the stigma of diagnosis – creates a powerful disincentive to visit a clinic. To be truly people-centered, we must move away from static clinic hours and towards flexible, community-based care that reaches men at places where they work.
Treating TB in isolation is an outdated strategy. We see patients suffering from a double burden because TB is usually accompanied by diabetes, malnutrition, or even HIV.
Despite this, our medical systems remain stubbornly reserved. A patient is often forced to navigate fragmented clinics that rarely communicate. Integration is the only way to ensure we treat the whole person, not just the pathogen.
The path forward requires us to acknowledge that we cannot end TB by looking only at the lungs; we must look at the lives of those affected. The end of TB is a matter of leadership and courage to fix the systems that hold medical science back.
As we look towards World Tuberculosis Day, let us not just renew our commitments; let us hold our systems to account. The human cost of cure is currently too high, not because of the medicine, but because of the world in which the medicine is delivered.
As we honor World Tuberculosis Day, let us ensure that no one else has to choose between finishing their life’s work and surviving a curable disease. Curing tuberculosis is no longer a biological mystery; it is a test of our collective humanity.
© 2024 Bennett, Coleman & Company Limited